Intermittent catheters are drawing volume away from continuous in-dwelling drainage, as more patients manage bladder conditions with single-use tubes instead of devices left in place for extended periods. The product line is compounding at 8.08% a year, well ahead of the market as a whole.
Contrive Datum Insights puts the global urinary catheters market at USD 6.3 billion in 2025, climbing to USD 6.68 billion in 2026 and USD 10.55 billion by 2034 (a compound annual growth rate of 5.88% across the forecast period). The figure comes from the company's report on the urinary catheters market, which breaks the market down by product, coating type, material, application, gender, end use, distribution channel and region through 2034.
A Shift in How Patients Manage Bladder Conditions
Rising rates of urinary incontinence and chronic urological conditions in aging populations sit behind most of the market's growth, and the study rates that driver's impact high. Intermittent Catheters carries the largest share of the exposure: its slice of revenue moves from 34% in 2025 to 41% by 2034, and its value from USD 2.142 billion to USD 4.326 billion.
Two scenarios bracket that trajectory. Faster reimbursement approval for self-catheterization products across Asia Pacific and Latin America could pull adoption forward and lift 2034 revenue to USD 11.605 billion. Tighter hospital procurement budgets and a slower rollout of home-care catheterization programs in Europe and North America work the other way, holding the same year to USD 9.284 billion.
Regional Balance Tips Toward Diversification
North America remains the largest regional market, holding 37% of 2025 revenue at USD 2.331 billion and reaching USD 3.587 billion by 2034. The United States alone accounts for USD 2.051 billion of that 2025 total, or 32.56% of global revenue. Asia Pacific is closing the distance: its share climbs from 24% in 2025 to 29% in 2034, with revenue rising from USD 1.512 billion to USD 3.06 billion. Middle East and Africa stays the smallest region across the period, holding at 6% of revenue in both years.
That regional spread has a product-line parallel. Indwelling (Foley) Catheters still carries the most revenue of any line, 42% in 2025 at USD 2.646 billion, and keeps the top spot through 2034 at a 36% share. Its growth rate, 4.07% a year, sits nearly two points under the market average; the dollars keep piling up, just more slowly than the rest of the portfolio. Intermittent Catheters runs the other direction: a smaller base today, expanding at nearly double the overall pace.
The full report breaks out revenue and growth for every segment from 2020 through 2034, models bear, base and bull scenarios for the market total, and details the competitive landscape and methodology behind each figure. It is delivered as a PDF, and a free sample is available on request from Contrive Datum Insights.